Macrophages have been shown to directly influence the growth and development of mature erythroid progenitors (CFU-E) in normal and erythroleukemic mice. W e examined the mechanism by which macrophages mediate their effect on in vivo erythropoiesis. As reported for whole macrophages, serum-free supernatants (SN) from normal resident peritoneal macrophages suppressed in vivo normal and conventional Friend virus (CFVI-infected CFU-E and caused clinical regression of CFV-induced leukemia in mice. Macrophage SN had no effect on the erythropoietin (EP0)-independent CFU-E characteristic of infection with the polycythemia-inducing strain of Friend virus (FVP), or progression of FVP leukemia. Using biochemical, immuno-H E CENTRAL REGULATOR of erythroid differenti-T ation is erythropoietin (EPO), a highly lineage-specific factor acting mainly on relatively late-stage erythroid progenitors.'.2 EPO is a stimulatory hormone, promoting growth and differentiation. However, it is also likely that there are negative regulators of the erythroid lineage whose physiologic role is to suppress or inhibit erythropoiesis a t times when there are sufficient red blood cells or when a shift to production of other hematopoietic end cells is required.
T ation is erythropoietin (EPO), a highly lineage-specific factor acting mainly on relatively late-stage erythroid progenitors.'.2 EPO is a stimulatory hormone, promoting growth and differentiation. However, it is also likely that there are negative regulators of the erythroid lineage whose physiologic role is to suppress or inhibit erythropoiesis a t times when there are sufficient red blood cells or when a shift to production of other hematopoietic end cells is required.
Macrophages are thought to play an important role in the control of erythropoiesis. This is based primarily on in vitro studies showing that macrophages inff uence colony formation by erythroid progenitor cell^.^-^ However, the mechanisms by which macrophages influence erythroid differentiation and the exact role of these effects in vivo remain largely unknown.
Studies in our laboratory have focused on the possibility that macrophages and their products are the negative regulators of erythropoiesis in vivo.6 These studies are based on the finding that infusion of normal macrophages into mice infected with the Friend murine leukemia virus (CFV), which causes a massive erythroid hyperplasia,' results in rapid hematologic and histopathologic reversal of the disease.' This appears to occur through restoration of normal macro-logic, and functional assays, the erythrosuppressive factor in macrophage SN was identified as interleukin-la (IL-la). The in vivo erythroid suppressive effects of macrophages, macrophage SN. and IL-1 a were reversed by simultaneous treatment with EPO. IL-la itself had no effect on CFU-E colony formation in vitro. Pretreatment of animals with antibodies to murine tumor necrosis factor-a (TNF-a) completely abrogated the suppression of CFU-E by macrophages, macrophage SN, or human recombinant IL-1 a.
These results suggest that macrophages regulate erythropoiesis by production of IL-la, which in turn mediates its in vivo suppressive effects on CFU-E through TNF. 0 1990 by The American Society of Hematology.
phage regulation of erythropoiesis.6 In the virus-infected animals, macrophages are themselves infected with the virus. As a result, they have lost this normal regulatory function and are incapable of causing regression or suppressing erythropoiesis. ' We report here that macrophages play this erythroid regulatory role through elaboration of a factor. The factor has been identified as interleukin-la (IL-la), a multifunctional cytokine with influences on a number of hematopoietic and nonhematopoietic Furthermore, we found that IL-la, which does not itself directly affect erythroid progenitors in vitro, acts by in vivo induction of tumor necrosis factor (TNF), a closely related cytokine that suppresses erythropoiesis both in vitro and in vivo. The effects of IL-I and TNF on erythropoiesis are reversed by EPO.
These interactions define a regulatory axis that appears to play an important role in the control of erythropoiesis and provides a mechanism for the hematopoietic response to physiologic conditions or stress, and the pathogenesis of the anemia of chronic disease.
MATERIALS AND METHODS

Mice.
These experiments were carried out in an inbred strain of Swiss mice (NIH/PLCR) that was originally obtained from the Veterinary Resources Branch, National Institutes of Health, and inbred in our laboratories by brother-sister mating. The colonies were regularly monitored for the absence of adventitious murine viruses. Mice were age-and sex-matched for experimental use and were assessed for leukemia and regression by spleen palpation biweekly in a blinded fashion, an accurate indicator of disease Regression is characterized by the restoration of normal spleen size (t0.5 g) and histology and a decrease in the amount of infectious virus recoverable from infected tissues and blood. At the termination of experiments, disease status was confirmed by spleen weight, virus assays, and/or histopathology. For hematopoietic colony assays, spleens were removed from three to five animals per treatment group and assayed individually. All experiments were fully replicated at least three times.
The N-tropic anemia-inducing (CFV) and poly- Normal resident peritoneal macrophages were plated in monolayer at a density of 5 x 106/mL in 35-mm tissue culturedishes and incubated at 37OC for 60 minutes. The nonadherent cells were removed by washing, and, in some instances, the macrophages were further purified by brief trypsinization (0.25% trypsin; GIBCO, Grand Island, NY; 3 minutes, 37OC) and washing with medium. Using this method, greater than 98% of the cells in the remaining monolayer are mature macrophages as determined by phagocytosis, expression of Fc receptors, nonspecific esterase activity, and reactivity with monospecific anti-macrophage serum.' Serum-free RPMI 1640 tissue culture medium (1 mL) was then added to each dish. After 48 hours incubation, medium was collected and frozen at -2OOC. All media components and trypsin solutions were tested for endotoxin contamination using the Limulus lysate assay and were used only if endotoxin was less than 0.01 ng/mL.
Erythroid progenitor cell assays. The plasma clot method of McLeod et all8 was used for the culture of mature erythroid progenitors (CFU-E) as previously des~ribed.'~,*~
Reagents and cells.
Preparation of macrophage supernatant. The mechanism by which macrophages suppress normal and leukemic erythropoiesis was initially evaluated by determining whether macrophages produce a soluble mediator of these effects. Supernatants (SN) were collected from cultures of purified populations of normal resident macrophages. Normal and 14-day CFV or FVP leukemic mice were inoculated IP with either 0.5 mL of macrophage SN or 5 x IO6 macrophages. After 5 days, numbers of CFU-E per total spleen were significantly suppressed in nurmal and CFV leukemic animals treated with either macrophage SN or macrophages (Table 1) . EPO-independent CFU-E, which characterize FVP leukemia, were not suppressed by either macrophage SN or macrophages. Suppression of CFU-E by macrophages is only observed in the spleen and not in the bone marrow of treated animak6 Likewise, no effect was observed on bone marrow CFU-E when normal or leukemic animals were treated with macrophage SN. The effect of macrophage SN on late-stage erythropoiesis in normal and leukemic animals was also manifest in peripheral blood reticulocyte counts. Similar to treatment with whole macrophages, the percent reticulocytes was decreased in normal mice treated with macrophage SN from 6.2 & 1.0 (SD) to 2.5 & 1.5 (10 to 15 animals per group, P < .001). In CFV leukemic mice, in which reticulocyte counts are elevated, macrophage SN also decreased the percent reticulocytes from 14.3 f 2.5 to 6.2 1.5 (P < .001).
RESULTS
Effect
We have previously reported that treatment of CFV leukemic mice with small numbers of resident peritoneal macrophages from normal animals causes clinical regression of their disease, whereas macrophage treatment of FVP leukemic mice has no effect6*' To determine whether macrophages also mediate leukemia regression through production of soluble factor(s), 14-day progressively leukemic mice were treated with a single injection of either 0.5 mL macrophage SN or 5 x lo6 normal resident macrophages. At day 35 post-virus, treatment with macrophage SN or whole macrqhages resulted in a significant percentage of regressions in CFV and not in FVP leukemic mice, as determined by spleen palpation ( Table 2) . As shown previously with transfer of macrophages: all CFV leukemic animals induced to regress by treatment with macrophage SN experienced disease recurrence 7 to 10 days later, characterized by an increase in spleen weight and absolute CFU-E number.
Identification of the active factor in macrophage SN. The results described above indicate that at both the hematologic and clinical levels, the effects of macrophages on normal and leukemic erythropoiesis are essentially duplicated by macrophage SN and are thus mediated by a soluble factor produced by the cells. Studies from our l a b o r a t o r i e~'~.~~ have also established that TNF-a and IL-la. well-character- tsignificantly different from control (medium treated), P < ,001 $Significantly different from control (medium treated), P < ,001
(Fisher exact probability test).
ized cytokines produced by macrophages, have in vivo effects on erythropoiesis similar to those of macrophages and macrophage SN, specifically.
To determine the nature of the erythrosuppressive factor in macrophage SN, studies were carried out to characterize the active component. The CFU-E suppressive activity was determined to be a protein by susceptibility to digestion with proteases and resistance to nucleases and lipases, and to have a molecular weight of about 15 to 20 Kd on the basis of ultrafiltration behavior through membranes with defined porosity, gel-filtration chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; data not shown).
These characteristics are compatible with the identity of the macrophage regulator of erythropoiesis as IL-1 or TNF. Assay of macrophage S N for IL-1 and T N F using in vitro bioassays (both the thymocyte and D10.G4.1 assays for IL-1 and the LM assay for TNF) revealed levels of 300 to 700 units/mL and 20 to 40 units/mL, respectively. Using isoelectric focusing in polyacrylamide gels and neutralization with a monospecific antibody against murine IL-la (with no crossreactivity against murine IL-16) the activity in macrophage S N was shown to be composed of both IL-la (35%) and To determine whether IL-1 or T N F mediated the CFU-E suppressive effects of macrophage SN, aliquots of the S N were treated in vitro with saturating amounts of specific antibodies against murine IL-la or murine TNF-a before injection. The specificities of these antisera and the lack of crossneutralization of the alternate cytokine were confirmed in in vitro assays with recombinant murine IL-la, IL-I@, and TNF-a. The amounts of antibody used were sufficient to neutralize lo2 and lo3 units of TNF-a and IL-la, respectively. Thus, the activity of macrophage S N in the LM assay for T N F was completely abrogated by the anti-murine TNF-a (data not shown). However, treatment with anti-TNF-a had no effect on the ability of macrophage S N to suppress spleen CFU-E in vivo. In contrast, treatment with anti-IL-la totally abrogated in vitro IL-la activity of macrophage SN and its in vivo activity (Table 3) . Control rabbit and goat IgGs had no effect, either alone or when
IL-16 (65%).
given with macrophage SN. Thus, the erythrosuppressive effects of macrophages and macrophage S N could be explained by production of IL-l a ; and antibody neutralization of the IL-la activity of macrophage SN, but not its TNF-a activity, inhibited its in vivo suppressive activity.
To further examine the relationship between IL-la production by macrophages and regulation of erythropoiesis, supernatants of the phorbol myristate acetate (PMA)-induced P388 murine monocytic leukemia cell line, a rich source of native murine IL-la,21 were tested for hematopoietic effects. Like macrophage SN, P388 supernatants actively suppressed CFU-E in vivo, and this activity was inhibited by pretreatment with anti-IL-la ( Table 4) . Tests of a number of independently prepared macrophage SNs revealed that suppression of CFU-E was generally proportional to IL-1 a content.
To establish that the effects of macrophage S N on erythropoiesis were not due to contaminating endotoxin, the endotoxin resistant mouse strain C3H/HeJ was used as recipient. Both macrophage S N and intact macrophages were fully effective in suppressing erythropoiesis in C3H/HeJ mice. Endotoxin levels of a number of preparations of macrophage SN, as determined by the limulus amoebocyte lysate assay, were consistently less than 0.01 ng/mL. Moreover, endotoxin-sensitive N/PLCR mice inoculated with up to 0.05 ng endotoxin per mouse (at least 10 times the maximum amount in macrophage S N inoculations) experienced no significant change in numbers of spleen CFU-E.
Suppression of erythropoiesis in normal mice by intact macrophages6 or by recombinant IL-lazo was observed in the EPO-dependent EfSect of endotoxin on erythropoiesis.
Reversal of CFU-E suppression by EPO. Aliquots of macrophage SN were treated in vitro for 1 hour at room temperature before injection with either 1 pg/mL of rabbit anti-TNF-a, 115 pglmL of goat anti-IL-la, or the same amounts of the respective IgG control. Mean f SD per total spleen was determined in three to five normal animals in each group that were assayed individually (three cultures counted per animal) 5 days after IP injection of 0.5 mL macrophage SN.
"Significantly different from control (medium treated, no antibody; individual animals), P < .OO 1.
?Percent change from control (medium treated, no antibody).
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From Aliquots of PMA-induced P388 supernatants were treated in vitro with 1 15 pg/mL of goat anti-IL-la or Ig as described in Table 3 .
"Mean f SD per total spleen was determined in three to five normal animals in each group that were assayed individually (three cultures counted per animal) 5 days after IP injection of 0.5 mL macrophage SN or P388 SN. tPercent change from control (medium treated).
$Significantly different than control (individual animals), P < ,001.
CFU-E but not in the EPO-independent BFU-E compartment. In addition, macrophage or IL-la induced suppression of CFU-E in vivo was reversed by simultaneous injection of EPO. To determine if the suppressive effects of macrophage S N were similarly related to EPO, animals were treated simultaneously with 0.5 mL macrophage S N and varying doses of recombinant human EPO (70,000 units/mg). EPO fully reversed the suppressive effects of macrophage S N on CFU-E ( Table 5 ) . EPO alone at this dose had no significant effect on spleen CFU-E numbers in normal animak6
As previously reported for erythrosuppression by IL-la,*' inoculation of the animal with serum-saturating quantities of iron or hemin did not reverse the effects of macrophage SN on CFU-E.
Mechanism of in vivo erythrosuppression by macrophage SN and IL-la. To examine the mechanisms by which 1L-la suppresses CFU-E in vivo, direct effects of the cytokine on CFU-E were tested in vitro. As previously reported,*' I L -l a had no effect on in vitro CFU-E colony formation, across a broad concentration range. However, TNF, which shares many biologic activities with IL-1 ,22 has been reported to directly suppress CFU-E in and the production of T N F is induced by IL-l.25 Based on these results, it appeared possible that the active component of macrophage SN, IL-la, mediates its in vivo effects by stimulation of release or production of TNF, which directly suppresses CFU-E. To test this, animals were treated with anti-murine TNF-a before inoculation with macrophages or macrophage SN. Similar pretreatment of animals with antibody to TNF-a prevents endotoxic shock and endotoxininduced hemorrhagic necrosis of tumors,26 both of which are mediated by TNF." As shown in Table 6 , animals treated with 10 pg of specific anti-TNF-a antibody 1 hour before injection with macrophage S N or intact macrophages (or human recombinant IL-la, data not shown) did not experience suppression of CFU-E. Pretreatment with control rabbit IgC had no effect on the CFU-E suppression observed with either macrophages or macrophage SN.
DISCUSSION
The results of this and preceding studies suggest the existence of an erythropoietic regulatory axis, based on the functional activities of macrophages, that counterbalances the effects of the principal erythroid stimulatory factor, EPO. The mechanism of this regulatory activity appears to be the production by normal, unstimulated macrophages of low levels of IL-la, a potent, multifunctional cytokine. The IL-l a , in turn, either directly or indirectly induces production of TNF-a, a closely related cytokine that suppresses growth and/or differentiation of late-stage erythroid progenitors. Completing this regulatory system is the finding that EPO reverses the suppressive effects of macrophages and their mediators.
The characterization of macrophage-produced IL-la as the initiator of this regulatory mechanism is supported by the following facts: the erythrosuppressive effects of macrophages can be reproduced by macrophage-conditioned media; the physical characteristics of the erythrosuppressive activity in the conditioned media are consistent with those of IL-la; these media contain significant levels of IL-la measured in the specific D10 assay; the erythrosuppressive effects of the macrophage SNs are related to their IL-la content; the effects of the macrophage SN are abrogated by specific antisera against IL-la; and the in vivo effects of macrophages and macrophage SN on erythropoiesis are replicated by recombinant human and murine IL-la. tsignificantly different from control (individual animals). P < ,001. $P < .05.
P < .01.
Despite these effects of macrophage-produced IL-la, the data suggest that IL-la itself is not the direct proximal mediator of erythrosuppression, since neither the cytokine" nor normal macrophages alone 28 had an effect on CFU-E colony formation in vitro. Instead, TNF-a, an IL-I-induced ~y t o k i n e~~.~~ whose spectrum of activities is very similar to that of IL-la" and that has been reported to inhibit CFU-E colony formation in ~i t r o , '~.~~ mediates the IL-la effect in vivo. This was demonstrated by the ability of anti-murine TNF-a to abrogate the in vivo effects of IL-la, macrophage SN, or macrophages.
Macrophage S N contained IL-la, IL-I@, and TNF. IL-la causes erythrosuppression in vivo,2o as do IL-l@29 and TNF.I9 Yet neutralization of only the IL-la was sufficient to fully abrogate the activity of macrophage SN. This could be due to quantitative differences in the effectiveness of the different cytokines; for example, the amount of pure murine T N F required to significantly suppress CFU-E is 10-to 100-fold higher than that present in macrophage SN. Alternatively, the principal mediator of the effect of macrophage S N could be IL-la, whose activity is enhanced by the presence of the other cytokines or additional mediators. Studies are currently in progress to address this issue.
The mechanism by which TNF-a ultimately causes erythrosuppression is unknown. TNF-a may act directly on CFU-E or through yet another mediator. Whatever the identity of the ultimate effector, the reversal of erythrosuppression by EPO is of interest, and suggests possible effects through the EPO receptor or its interaction with the hormone.
These studies used normal, briefly cultured, resident peritoneal macrophages and their products as the mediators of erythrosuppression. The same results are obtained using macrophages directly transferred from animal to animal without in vitro culture or adherence.6 It is generally considered that production of IL-la (and TNF-a) by such cells is minimal, and induced to high levels only after activati~n.'~-'~ Obviously, as shown in this report, the basal levels of IL-la produced by these nonactivated macrophages is sufficient to mediate significant erythrosuppression in vivo. As noted above, these basal levels of IL-la in macrophage SN may be more effective than purified or recombinant IL-I alone because of interaction with other mediators (IL-18, interfer- ons, or TNF) in the preparation.
The amounts of IL-la produced by the macrophages in these studies and the ultimate in vivo effects observed are not due to endotoxin contamination. All media and components were found to be free of significant endotoxin levels using the limulus lysate assay, and endotoxin at 10-fold higher than the maximum amount in macrophage S N did not cause erythrosuppression. The same erythroid effects were also observed in endotoxin-sensitive and endotoxin-resistant mouse strains. Furthermore, it is unlikely that culturing the macrophages induced production of the IL-la mediating erythrosuppression, since direct transfer of macrophages from animal to animal without culture or adherence has the same effects on CFU-E.
On the other hand, it would seem likely that macrophages activated in an inflammatory or infectious process would produce higher amounts of IL-la, and thus cause greater or more sustained erythrosuppression. This could serve the purpose of shunting hematopoiesis towards production of defensive monocytic and granulocytic cells. IL-1 itself is also a potent in vivo inducer of granulocyte-macrophage colonystimulating factor (GM-CSF)31.32 as well as other cytokines,22 plays a role in T and B cell and is one of the mediators of the acute phase response,34 providing a major positive reactive stimulus to infection as well. Thus, macrophages and their products serve as a regulatory link between the erythroid lineage and the defensive components (granulocytes, lymphocytes) of the hematopoietic system. Finally, continuous activation of macrophages, which occurs in a number of diseases, could result in sustained elevation of IL-I (and TNF) and, thus, could be involved in the pathogenesis of the anemia of chronic disease. This is currently under study.
The finding that IL-la had no effect on CFU-E colony formation in vitro appears to conflict with the report by Schooley et aI3' that IL-la reduced 'H-thymidine incorporation into spleen cells cultured in the presence of EPO. However, the substantial differences in the nature and specificity of the assay methods is a likely explanation for the contrasting results.
Similar to the findings we report here with recombinant IL-I a, we have previously reported that intact normal macrophages have no effect on CFU-E colony formation in vitro.28 Indeed, activated macrophages stimulated in vitro CFU-E colony formation. These results suggest that it is not the resident macrophages themselves that produce the more proximal suppressive factor, TNF, and also that macrophages in different states of activation may produce several factors with different effects on CFU-E. Furthermore, while the production of 1L-la explains the in vivo erythrosuppressive effects of macrophages, IL-la is probably not the only For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From hematopoietic mediator produced by macrophages: the cells are known to produce prostaglandins, CSFs, and other factors with effects on various hematopoietic lineages.
Del Rizzo et a1 have identified and characterized a protein in bone marrow cell supernatants that negatively regulates DNA synthesis in burst-forming units-erythroid (BFU-E).36 This protein is related to FV-2 gene-mediated resistance to FV infection and may function in regulating steady-state levels of replication in the BFU-E compartment. The physical characteristics of this factor are quite different from IL-1 and TNF, which in contrast increase numbers of BFU-E in vivo. Nevertheless, this factor and others could be involved, together with IL-I and TNF, in overall regulation of erythropoiesis.
These studies were initiated with the observation that treatment of CFV erythroleukemic mice with relatively small numbers of resident peritoneal macrophages from normal animals causes a dramatic, but transient, clinical regression of the disease? We subsequently showed that the effects of macrophages were localized to the CFU-E compartment, and affected normal and EPO-dependent CFU-E of CFV-infected animals, but not the EPO-independent CFU-E of FVP leukemics.6 In leukemic animals, macrophages become infected with the virus and functionally defective? Infected macrophages do not induce leukemia regression. Treatment of CFV infected animals with either IL-la or TNF-a will cause permanent disease regressions." Taken together with the present results, it is suggested that the erythroid hyperplasia characteristic of CFV leukemias (EPOdependent forms) is the result of a defect in the normal regulatory constraints on erythropoiesis posed by macrophages and their products. This may be due to diminished production of IL-la by infected macrophages, or defective induction of TNF-a by IL-la in infected animals. Further elucidation of the erythroid regulatory defect in leukemic animals could provide additional insight into the pathogenesis of this and related diseases and new approaches to their treatment.
